• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern

tetano

Editor, Senior Moderator
Cell Rep


. 2021 Dec 15;110210.
doi: 10.1016/j.celrep.2021.110210. Online ahead of print.
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern


Wenwei Li[SUP] 1 [/SUP], Yaozong Chen[SUP] 2 [/SUP], Jérémie Prévost[SUP] 3 [/SUP], Irfan Ullah[SUP] 4 [/SUP], Maolin Lu[SUP] 1 [/SUP], Shang Yu Gong[SUP] 5 [/SUP], Alexandra Tauzin[SUP] 3 [/SUP], Romain Gasser[SUP] 3 [/SUP], Dani Vézina[SUP] 3 [/SUP], Sai Priya Anand[SUP] 5 [/SUP], Guillaume Goyette[SUP] 6 [/SUP], Debashree Chaterjee[SUP] 6 [/SUP], Shilei Ding[SUP] 6 [/SUP], William D Tolbert[SUP] 2 [/SUP], Michael W Grunst[SUP] 1 [/SUP], Yuxia Bo[SUP] 7 [/SUP], Shijian Zhang[SUP] 8 [/SUP], Jonathan Richard[SUP] 3 [/SUP], Fei Zhou[SUP] 9 [/SUP], Rick K Huang[SUP] 9 [/SUP], Lothar Esser[SUP] 9 [/SUP], Allison Zeher[SUP] 9 [/SUP], Marceline Côté[SUP] 7 [/SUP], Priti Kumar[SUP] 4 [/SUP], Joseph Sodroski[SUP] 8 [/SUP], Di Xia[SUP] 9 [/SUP], Pradeep D Uchil[SUP] 1 [/SUP], Marzena Pazgier[SUP] 10 [/SUP], Andrés Finzi[SUP] 11 [/SUP], Walther Mothes[SUP] 12 [/SUP]



Affiliations

Abstract

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can transmit more efficiently and partially evade protective immune responses, thus necessitating continued refinement of antibody therapies and immunogen design. Here, we elucidate the structural basis and mode of action for two potent SARS-CoV-2 spike (S)-neutralizing monoclonal antibodies, CV3-1 and CV3-25, which remain effective against emerging variants of concern in vitro and in vivo. CV3-1 binds to the (485-GFN-487) loop within the receptor-binding domain (RBD) in the "RBD-up" position and triggers potent shedding of the S1 subunit. In contrast, CV3-25 inhibits membrane fusion by binding to an epitope in the stem helix region of the S2 subunit that is highly conserved among β-coronaviruses. Thus, vaccine immunogen designs that incorporate the conserved regions in the RBD and stem helix region are candidates to elicit pan-coronavirus protective immune responses.

Keywords: COVID-19; SARS-CoV-2; emerging variants of concern; epitopes; neutralizing antibodies; receptor-binding domain; β-coronaviruses.
 
Back
Top Bottom